Medicilon once again ranked on the 2024 Shanghai Hard Core Technology Enterprises TOP100 List

On March 22, the 2024 Shanghai Industrial Technology Innovation Conference was held with the theme of "Building the Main Engine of Innovation and Seizing New Opportunities in the Future". At this conference, Medicilon won the "2024 Shanghai Hard Core Technology Enterprises TOP100 List" with its hard-core technology and innovative technology service platform in the preclinical field of biopharmaceutical.

Medicilon once again ranked on the 2024 Shanghai Hard Core Technology Enterprises TOP100 List.webp

As a one-stop biopharmaceutical preclinical R&D service platform, Medicilon has always been committed to exploring hard-core technologies in the biopharmaceutical preclinical field. After 20 years of development, Medicilon now has 84,000 square meters of R&D laboratories and a high-quality R&D team. Through continuous technological innovation and R&D investment, we have conquered the core R&D technologies of new molecular types of drugs such as antibodies, peptides, ADCs, PROTACs, mRNA vaccines, small nucleic acid drugs, cell & gene therapy (CGT), and established a R&D service platform to empower and accelerate global pharmaceutical innovation. At the same time, Medicilon also has a wealth of innovative drug molecule design technology, relying on computer-aided drug design technology, high-throughput drug discovery technology, and bioelectronic isostere technology to establish a more efficient AI-guided drug design and synthesis platform to help clients improve R&D efficiency and reduce R&D barriers.

It is these hard-core scientific and technological innovation capabilities that have enabled Medicilon to empower 421 IND-approved clinical trials in the biopharmaceutical preclinical field, winning widespread recognition and praise, and attracting the favor of many partners. Looking forward to the future, Medicilon will continue to stride forward on the journey of technological innovation and industrial development, injecting continuous innovative vitality and power into the global biopharmaceutical industry!

此博客中的热门博文

What is preclinical testing?

In the process of preclinical testing of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a preclinical research phase followed, before which, as described above, the potential toxicity of the compou

阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati

阅读全文

Shanghai Medicilon Inc.

搜索此博客